Try Premium for 30 days

Live games for all NFL, MLB, NBA, & NHL teams
Commercial-Free Music
No Display Ads
Food and Drug Administration Drug Safety Podcast-logo

Food and Drug Administration Drug Safety Podcast

Government >

The FDA Drug Safety Podcasts provide emerging safety information about drugs in conjunction with the release of Public Health Advisories.

The FDA Drug Safety Podcasts provide emerging safety information about drugs in conjunction with the release of Public Health Advisories.
More Information

Location:

United States

Description:

The FDA Drug Safety Podcasts provide emerging safety information about drugs in conjunction with the release of Public Health Advisories.

Language:

English


Episodes

FDA Drug Safety Podcast: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

12/26/2017
More
On December 20, 2017, an Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.

Duration: 00:00:01


FDA Drug Safety Podcast: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)

11/20/2017
More
On November 15, 2017, FDA alerted the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (brand name Uloric) compared to another gout medicine called allopurinol. We required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when we approved the medicine in 2009.

Duration: 00:02:59


FDA Drug Safety Podcast: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease

10/4/2017
More
On September 21, 2017, FDA warned that the liver disease medicine Ocaliva (active ingredient obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death.

Duration: 00:02:59


FDA Drug Safety Podcast: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks

10/2/2017
More
Based on our additional review, the U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS).

Duration: 00:03:29


FFDA Drug Safety Podcast: FDA recommends separating dosing of potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs

9/14/2017
More
On September 6, 2017 FDA recommended that patients avoid taking the potassium-lowering drug sodium polystyrene sulfonate (brand name Kayexalate) at the same time as any other medicines taken by mouth.

Duration: 00:02:59